

Annual document pursuant to Section 10 of the German Securities Prospectus Act (“Wertpapierprospektgesetz” or “WpPG”)

Pursuant to Section 10 of the WpPG entered into force as from July, 1 2005, biolitec must at least once annually make available to the public a document containing or referring to all information which biolitec has published or made available to the public during the past twelve months. In the following document biolitec has summarized all information published or made available to the public in a so called annual document as specified in Section 10 Paragraph 1 of the WpPG for the period from July, 1 2005 until June, 30 2006.

Ad - hoc - Release (§15 WpHG)	Date of Release	Availability / Published in
biolitec AG: Joint Venture in Japan	21.7.2005	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG: Temoporfin shows amazing results in cellulite treatment	4.8.2005	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG achieved revenues of Euro 24.9 millions in fiscal year 04/05	16.9.2005	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG achieved revenues of Euro 5.65 millions in the first quarter	30.11.2005	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG receives FDA approval and CE mark for AMD laser system	11.1.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
First half year revenue of biolitec AG increases at about 20 percent – extra impulses expected for the second half year	28.2.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG expects revenue leap from urological applications – first contract signed	10.5.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
Innovative vein therapy based on biolitec's Temoporfine unveiled – Worldwide potential about 500.000 cases	16.5.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG continues its growth – substantial profit increase in the first nine months	31.5.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
Ad-Hoc-Correction	1.6.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG expects further increase of orders for urology laser – Additional revenue of about Euro 5,4 million	28.6.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05

Press Release	Date of Release	Availability / Published in (Only available in German)
biolitec AG gründet Joint Venture in Japan	5.7.2005	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
biolitec AG erhält Forschungsgelder vom BMBF für neuartige Sepsistherapie	12.7.2005	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
biolitec AG: Temoporfin zeigt erstaunliche Ergebnisse in der Cellulitebehandlung	4.8.2005	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Bahnbrechender Erfolg bei der Cellulite-Behandlung mit neuem Wirkstoff der biolitec AG	14.9.2005	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01

biolitec AG erhält Forschungsgelder für Hochleistungs-Laserentwicklung	18.10.2005	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Neue Cellulite-Therapie mit Temporfin überrascht mit sensationellen Ergebnissen in Südamerika	24.10.2005	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Neue LaEvita-AntiCellulite-Therapie in deutschen Schönheits-Kliniken erfolgreich gestartet	6.2.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Biolitec entwickelt Laser zur Heilung und Behandlung großflächiger Wunden	2.3.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Gesetzliche Krankenkasse prüft Kostenübernahme bei Modellprojekt mit Krampfader-Therapieverfahren ELVeS™ von biolitec	3.4.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Zulassungsstudie für ELVeS™-Venenbehandlungssystem in Japan gestartet	12.4.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Biolitec expandiert mit LaEvita-Cellulite-Therapie europaweit – Renommierte ungarische Schönheitsklinik setzt auf neue Cellulite-Behandlungsmethode	4.5.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
Neuer Urologielaser der biolitec AG mit internationalen Absatzerfolgen – minimal invasives Behandlungsverfahren für die benigne Prostatahyperplasie nun auch in Deutschland	10.5.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
LaEvita™ Cellulite-Therapie überzeugt durch 6-Monats-Follow-up-Ergebnisse – ein Highlight der Jornadas Mediterráneas de Confrontaciones Terapéuticas en Medicina y Cirugía Cosmética	15.5.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
biolitec stellt bemerkenswerte Resultate einer neuen Venentherapie auf internationaler Konferenz vor	17.5.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01
biolitec AG vervielfacht 9-Monats-Überschuss auf 0,9 Millionen Euro	2.6.2006	http://www.biolitec.com/german/news/pressreleases.asp?m=news&s=01

Reports (Annual Financial Statement / Quarterly Reports)	Date of Release	Availability / Published in
Annual Report 2004/2005	30.9.2005	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06
3 Months Report	30.11.2005	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06
6 Months Report	28.2.2006	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06
9 Months Report	31.5.2006	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06

Annual General Meeting		(Only available in German)
Einladung zur Hauptversammlung 2006 inklusive Tagesordnung	23.9.2005	http://www.biolitec.com/german/ir/generalmeeting.asp?m=ir&s=12
Geschäftsbericht 2005/2006	30.9.2005	http://www.biolitec.com/german/ir/generalmeeting.asp?m=ir&s=12
Einzelabschluss biolitec AG	30.9.2005	http://www.biolitec.com/german/ir/generalmeeting.asp?m=ir&s=12
Vollmacht für Stimmrechtsvertreter	23.9.2005	http://www.biolitec.com/german/ir/generalmeeting.asp?m=ir&s=12
Erklärung Dt. Corporate Governance Kodex	23.8.2005	http://www.biolitec.com/german/ir/generalmeeting.asp?m=ir&s=12
AR-Bericht für das Geschäftsjahr 05/06 gemäß § 171 Abs. 2 AktG	9.9.2005	http://www.biolitec.com/german/ir/generalmeeting.asp?m=ir&s=12
Bestätigungsvermerk des Wirtschaftsprüfers zum Jahresabschluss	9.9.2005	http://www.biolitec.com/german/ir/generalmeeting.asp?m=ir&s=12

Releases according to section (§25 WpHG)	Date of Release	Availability / Published in
-	-	-

Disclosure of securities transactions - Notifications pursuant to section 15a WpHG	Date of Release	Availability / Published in
-	-	-

Other Documents	Date of Release	Availability / Published in
-	-	-